Actuate Therapeutics EBIT

Actuate Therapeutics (ACTU) currently reports a EBIT of $-21M as of June 2026. That compares with $-24M in the prior-year period — up 14.4% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore Actuate Therapeutics's EBIT history and peer comparisons.

Actuate Therapeutics's EBIT increased from $-24M to $-21M — a 14.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Actuate Therapeutics's EBIT of $-21M is lower than the its sector sector average of $-6.4M. That is roughly 224.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Actuate Therapeutics reported $-21M in EBIT as of June 2026. That compares with $-24M in the prior-year period — up 14.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-21M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Actuate Therapeutics, and consider following ACTU for alerts when major investors trade the stock.